TLDR:
- Autonomix sees 61.76% stock surge after European patent grant.
- Patent No. EP4230133 revolutionizes cardiac treatment with neuromodulation.
- Autonomix’s tech targets arrhythmia, hypertension, and heart failure.
- CEO highlights patent’s role in expanding Autonomix’s global IP portflio.
- Company aims to transform cardiology and chronic pain management.
Autonomix Medical, Inc. (AMIX) has seen a substantial rise in its stock price after securing a key European patent. As of 9:30 AM EST, the stock reached $0.8660, reflecting a sharp increase of 61.76%.
Autonomix Medical, Inc. Common Stock, AMIX
This surge follows the European Patent Office’s recent grant of Patent No. EP4230133, covering innovations in cardiac treatment technologies.
Patent Approval Marks Significant Milestone
The newly granted patent includes systems, devices, and methods for treating cardiac tissues through precise neuromodulation and feedback-driven therapy. These innovations allow for controlled and accurate treatment of cardiac tissues by mapping autonomic signals and providing targeted therapy. With this patent, Autonomix expands its intellectual property portfolio and strengthens its technology platform aimed at transforming cardiac treatments.
CEO Brad Hauser highlighted the importance of the patent for the company’s long-term strategy. “This patent expands the global IP foundation supporting our breakthrough technologies,” Hauser said. The patent builds on their previously granted U.S. patent, enhancing Autonomix’s ability to provide precision therapies in cardiology, including hypertension management, arrhythmia treatment, and heart failure.
The company sees vast potential in the application of this technology across several therapeutic areas. The patent covers various conditions, including arrhythmias, refractory angina, myocardial infarction risk, and hypertension. The company’s platform offers feedback-driven denervation, which may reduce the reliance on systemic beta blockers and related side effects.
Autonomix’s Expanding Technological Platform
Autonomix Medical’s technology focuses on precision nerve-targeted treatments that promise to revolutionize disease diagnosis and management. Their platform uses a catheter-based microchip sensing array, designed to detect and differentiate neural signals with greater sensitivity. This platform opens new possibilities for the diagnosis and treatment of diseases involving the peripheral nervous system.
The company’s initial trials focus on pancreatic cancer pain, a condition with limited treatment options. The technology addresses other high-need areas, including cardiology, hypertension, and chronic pain management. Autonomix aims to provide breakthrough solutions for a wide spectrum of diseases by leveraging its unique platform.
Autonomix Medical’s research and development efforts continue to drive forward with its promising technology. The company has not yet cleared the technology for marketing in the United States but remains focused on expanding its global footprint. The grant of this patent marks a significant achievement in the company’s ongoing mission to advance nerve-targeted therapies.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
